Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
暂无分享,去创建一个
A. Kishan | R. Mehra | H. Sandler | R. Dess | B. Mahal | W. Jackson | T. Morgan | P. Nguyen | F. Feng | M. Schipper | D. Spratt | E. Schaeffer | N. Jairath | K. Fizazi | J. Alumkal | S. Halabi | Z. Reichert | E. Jaworski | D. Wallington | Gavin S Jones | S. Birer | L. Gharzai | D. Elliott | R. Jiang | M. McFarlane | P. Nguyen | Gavin S. Jones
[1] D. Berry,et al. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] W. R. Lee,et al. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. , 2020, JAMA oncology.
[3] D. Gorovets,et al. Financial toxicity associated with treatment of localized prostate cancer , 2019, Nature Reviews Urology.
[4] D. Spratt,et al. Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer. , 2019, International journal of radiation oncology, biology, physics.
[5] D. Kuban,et al. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. , 2019, International journal of radiation oncology, biology, physics.
[6] L. Collette,et al. A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses , 2019, JNCI cancer spectrum.
[7] T. J. Moore,et al. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016 , 2018, JAMA internal medicine.
[8] H. Sandler,et al. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial , 2018, JAMA oncology.
[9] P. Kantoff,et al. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W. J. Morris,et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.
[11] Amber Jessup,et al. Key cost drivers of pharmaceutical clinical trials in the United States , 2016, Clinical trials.
[12] P. Kantoff,et al. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). , 2015, Journal of the National Cancer Institute.
[13] B. Kramer,et al. Surrogate endpoint analysis: an exercise in extrapolation. , 2013, Journal of the National Cancer Institute.
[14] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].
[15] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[16] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[17] A. Renshaw,et al. Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .
[18] M. Gail,et al. The promise and peril of surrogate end points in cancer research , 2002, Nature Reviews Cancer.